Karyopharm Therapeutics Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
22.7M
on 2026-06-30, from 7.76M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-15 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
$400.0M
S-3 of 2026-05-04. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗
$100.0M
Jefferies, agreement of 2026-05-04. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗
Warrants
18.05M
Warrants of every class as tagged in the XBRL facts on 2026-06-30, exercise price $0.0001. 10-Q ↗
Cash
4 quarters
$65.1M on 2026-06-30 ÷ $16.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-03-24 | Private placement incl. 3.39M pre-funded | 4,421,518 | $6.785 | $30.0M | 8-K ↗ |
| 2025-10-08 | Private placement incl. 2.91M pre-funded | 10,137,118 | not read | $8.8M | 8-K ↗ |
Also on file: a 1-for-15 reverse split, 2025-02-24 8-K ↗ · $15.0M revenue notes, 2025-10-07 8-K ↗